Until now, Sativex has been approved for use on the NHS in England, Wales and Northern Ireland, but not in Scotland.
A Phase II trial of Sativex, in patients with the most severe form of brain tumour, will open in 2022.
Thousands of MS patients are being denied access to Sativex, despite it receiving NICE approval two years ago.
